Cargando…
Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues
Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing...
Autores principales: | Porta, Sabrina, Danza, Alvaro, Arias Saavedra, Maira, Carlomagno, Adriana, Goizueta, María Cecilia, Vivero, Florencia, Ruiz-Irastorza, Guillermo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563630/ https://www.ncbi.nlm.nih.gov/pubmed/32839376 http://dx.doi.org/10.3390/jcm9092709 |
Ejemplares similares
-
Predictors of major infections in systemic lupus erythematosus
por: Ruiz-Irastorza, Guillermo, et al.
Publicado: (2009) -
TEN Like Lupus: A Rare Initial Presentation of Lupus Erythematosus
por: Kumar, Richa, et al.
Publicado: (2022) -
Glucocorticoid‐induced osteonecrosis in systemic lupus erythematosus patients
por: Kaneko, Kaichi, et al.
Publicado: (2021) -
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
por: Ruiz-Irastorza, Guillermo, et al.
Publicado: (2020) -
To target or not to target APRIL in systemic lupus erythematosus: that is the question!
por: Morel, Jacques, et al.
Publicado: (2013)